AC Immune (ACIU) Competitors

$2.77 -0.02 (-0.72%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$2.82 +0.05 (+1.81%)

As of 03:59 AM Eastern

ACIU vs. HROW, DBVT, SEPN, XERS, and EVO

Should you buy AC Immune stock or one of its competitors? MarketBeat compares AC Immune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AC Immune include Harrow (HROW), DBV Technologies (DBVT), Septerna (SEPN), Xeris Biopharma (XERS), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry.

How does AC Immune compare to Harrow?

Harrow (NASDAQ:HROW) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Harrow presently has a consensus price target of $69.43, indicating a potential upside of 124.69%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 170.76%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

72.8% of Harrow shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Harrow has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

Harrow has a net margin of -5.57% compared to AC Immune's net margin of -1,788.02%. Harrow's return on equity of 19.59% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
AC Immune	-1,788.02%	-125.26%	-40.85%

In the previous week, Harrow had 6 more articles in the media than AC Immune. MarketBeat recorded 13 mentions for Harrow and 7 mentions for AC Immune. AC Immune's average media sentiment score of 0.95 beat Harrow's score of 0.14 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has higher revenue and earnings than AC Immune. Harrow is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	4.23	-$5.14M	-$0.41	N/A
AC Immune	$4.31M	65.41	-$85.03M	-$0.82	N/A

Summary

Harrow beats AC Immune on 11 of the 16 factors compared between the two stocks.

How does AC Immune compare to DBV Technologies?

AC Immune (NASDAQ:ACIU) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

AC Immune has higher earnings, but lower revenue than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	65.41	-$85.03M	-$0.82	N/A
DBV Technologies	$5.64M	196.84	-$146.95M	-$4.46	N/A

51.4% of AC Immune shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AC Immune has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, suggesting that its share price is 196% less volatile than the broader market.

In the previous week, AC Immune had 3 more articles in the media than DBV Technologies. MarketBeat recorded 7 mentions for AC Immune and 4 mentions for DBV Technologies. AC Immune's average media sentiment score of 0.95 beat DBV Technologies' score of 0.37 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 170.76%. DBV Technologies has a consensus target price of $40.25, suggesting a potential upside of 114.67%. Given AC Immune's higher probable upside, equities analysts plainly believe AC Immune is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -2,895.37%. AC Immune's return on equity of -125.26% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Summary

AC Immune beats DBV Technologies on 11 of the 17 factors compared between the two stocks.

How does AC Immune compare to Septerna?

Septerna (NASDAQ:SEPN) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Septerna has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

51.4% of AC Immune shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Septerna presently has a consensus price target of $43.13, indicating a potential upside of 63.97%. AC Immune has a consensus price target of $7.50, indicating a potential upside of 170.76%. Given AC Immune's higher probable upside, analysts clearly believe AC Immune is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Septerna had 9 more articles in the media than AC Immune. MarketBeat recorded 16 mentions for Septerna and 7 mentions for AC Immune. AC Immune's average media sentiment score of 0.95 beat Septerna's score of -0.06 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has a net margin of -49.88% compared to AC Immune's net margin of -1,788.02%. Septerna's return on equity of -12.72% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
AC Immune	-1,788.02%	-125.26%	-40.85%

Septerna has higher revenue and earnings than AC Immune. Septerna is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	25.80	-$48.88M	-$0.81	N/A
AC Immune	$4.31M	65.41	-$85.03M	-$0.82	N/A

Summary

Septerna beats AC Immune on 11 of the 17 factors compared between the two stocks.

How does AC Immune compare to Xeris Biopharma?

AC Immune (NASDAQ:ACIU) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Xeris Biopharma has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	65.41	-$85.03M	-$0.82	N/A
Xeris Biopharma	$291.85M	3.56	$550K	$0.06	100.17

In the previous week, AC Immune had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for AC Immune and 6 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.07 beat AC Immune's score of 0.95 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AC Immune has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Xeris Biopharma has a net margin of 3.81% compared to AC Immune's net margin of -1,788.02%. Xeris Biopharma's return on equity of 735.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Xeris Biopharma	3.81%	735.00%	3.24%

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 170.76%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 79.70%. Given AC Immune's higher probable upside, equities research analysts clearly believe AC Immune is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Xeris Biopharma beats AC Immune on 10 of the 16 factors compared between the two stocks.

How does AC Immune compare to Evotec?

AC Immune (NASDAQ:ACIU) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, AC Immune had 5 more articles in the media than Evotec. MarketBeat recorded 7 mentions for AC Immune and 2 mentions for Evotec. AC Immune's average media sentiment score of 0.95 beat Evotec's score of 0.56 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evotec has a net margin of -26.20% compared to AC Immune's net margin of -1,788.02%. Evotec's return on equity of -24.93% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Evotec	-26.20%	-24.93%	-11.35%

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 170.76%. Evotec has a consensus price target of $7.00, suggesting a potential upside of 155.47%. Given AC Immune's higher possible upside, research analysts plainly believe AC Immune is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AC Immune has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	65.41	-$85.03M	-$0.82	N/A
Evotec	$891.97M	1.09	-$117.12M	N/A	N/A

AC Immune has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

Summary

AC Immune and Evotec tied by winning 7 of the 14 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$283.95M	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-3.38	18.13	20.63	25.23
Price / Sales	65.41	289.87	554.93	79.80
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	5.13	6.57	9.69	6.63
Net Income	-$85.03M	$24.35M	$3.56B	$335.59M
7 Day Performance	N/A	-2.53%	-1.63%	-1.20%
1 Month Performance	-7.97%	-3.55%	-2.59%	-1.16%
1 Year Performance	59.20%	53.51%	30.08%	28.10%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.532 of 5 stars	$2.77 -0.7%	$7.50 +170.8%	+62.0%	$283.95M	$4.31M	N/A	140
HROW Harrow	4.0396 of 5 stars	$30.26 -20.5%	$69.86 +130.9%	+8.8%	$1.13B	$272.30M	N/A	180	Analyst Downgrade Analyst Revision Gap Down High Trading Volume
DBVT DBV Technologies	2.909 of 5 stars	$20.12 -1.2%	$40.25 +100.0%	+68.9%	$1.12B	$5.64M	N/A	80
SEPN Septerna	3.151 of 5 stars	$24.14 +2.4%	$43.13 +78.6%	+167.3%	$1.09B	$45.95M	N/A	N/A	Earnings Report Upcoming Earnings
XERS Xeris Biopharma	3.2945 of 5 stars	$6.25 +1.7%	$10.80 +72.9%	+23.2%	$1.08B	$291.85M	104.08	290	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors